INTRODUCTION
============

Stem cells are a population of unspecialized cells with the ability to both self-renew and give rise to multiple cell types ([@b2-bt-28-034]). The stem cell niche consists of a heterogeneous cell population, extracellular matrix and different soluble factors, which together provide a suitable microenvironment ([@b21-bt-28-034]) for the maintenance of these cells. Stem cells can be classified according to their differentiation capacity into: i) totipotent stem cells, which can generate all cell types of the organism, including embryonic and extraembryonic tissues ([@b75-bt-28-034]); ii) pluripotent stem cells, which can differentiate into cell types from any of the three germ layers, thus being able to differentiate into all cells of the adult organism ([@b53-bt-28-034]); iii) multipotent stem cells, which can give rise to all cells derived from one specific lineage ([@b40-bt-28-034]); and finally, iv) unipotent stem cells, which can only generate one cell type ([@b38-bt-28-034]).

Despite sharing common properties, stem cells exhibit different features when they originate from different sources ([@b42-bt-28-034]). In fact, stem cells can be categorized as embryonic stem cells (ESCs), fetal stem cells (FSCs), perinatal stem cells (PSCs), adult stem cells (ASCs) and induced pluripotent stem cells (iPSCs). ESCs have the advantage of being pluripotent, although their use involves high risk of tumorigenicity and generates a great ethical controversy, since they derive from embryo at the blastocyst stage ([@b62-bt-28-034]). Interestingly, iPSCs have similar characteristics to ESCs, including pluripotency, but are generated from adult somatic cells by epigenetic reprogramming and thus they can be used without ethical debate ([@b68-bt-28-034]). FSCs are derived from fetal tissues, even though they exhibit a lower division capacity than ESCs ([@b37-bt-28-034]). PSCs are multipotent cells that derive from perinatal extraembryonic tissues and share properties with ESCs and ASCs ([@b72-bt-28-034]). The latter, i.e., ASCs, are multipotent cells present in most adult tissues, where they play a key role in tissue regeneration ([@b62-bt-28-034]; [@b53-bt-28-034]).

The exciting potential of stem cells in tissue regeneration and repair provides an alternative approach to cell-based therapies in various diseases, especially in those that affect the nervous system (NS) ([@b26-bt-28-034]). In fact, stem cells may replace some non-functional cells in neurodegenerative disorders and NS lesions ([@b52-bt-28-034]). In this context, mesenchymal stem cells (MSCs), which are adult stem cells derived from the mesoderm and neuroectoderm ([@b21-bt-28-034]), exhibit a high differentiation plasticity. These cells present some advantages compared to other stem cells such as neural stem cells (NSCs), namely lack of teratoma formation capacity since they derive from adult tissues and ability to migrate towards inflammatory foci through expression of chemokine receptors ([@b35-bt-28-034]; [@b81-bt-28-034]; [@b46-bt-28-034]; [@b23-bt-28-034]). Moreover, the use of MSCs could avoid the toxicity of the immunosuppressive regimens used with NCS ([@b25-bt-28-034]).

Previous review articles have discussed the MSCs ability to differentiate into neurons and their possible application in clinical trials ([@b69-bt-28-034]; [@b80-bt-28-034]; [@b74-bt-28-034]). This review summarizes the potential of MSCs in regenerative medicine applied to neurological disorders, and offers a comprehensive compilation of the most recent clinical studies that employ this type of cell therapy.

MESENCHYMAL STEM CELLS
======================

MSCs are considered multipotent cells able to give rise to all cell types of mesodermal origin, including bone, cartilage and fat cells. However, their ability to differentiate into non-mesodermal cell types such as neurons has been widely reported ([@b19-bt-28-034]; [@b68-bt-28-034]). Although these cells were isolated for the first time from bone marrow ([@b24-bt-28-034]), they reside in almost all tissues, with adipose tissue, placenta and umbilical cord being the most used MSC sources ([@b21-bt-28-034]; [@b77-bt-28-034]).

In recent decades, MSCs have been hailed as a therapeutic promise in regenerative medicine due to their accessibility and ease of *in vitro* expansion, reduced immunogenic properties ([@b68-bt-28-034]) and broad differentiation ability compared to other ASCs types ([@b19-bt-28-034]; [@b21-bt-28-034]). The International Society for Cellular Therapy (ISCT) established three minimal criteria for the correct identification of MSCs: i) plastic adherence; ii) positive expression of the CD73, CD90 and CD105 markers and negative for CD34, CD45, HLA-DR, CD14 or CD11B, CD79α or CD19; and iii) capacity of *in vitro* differentiation into adipocytes, chondrocytes and osteoblasts ([@b77-bt-28-034]). Nevertheless, it has been reported that these stem cells may have variable biological features according to the source, the donor or the culture conditions ([@b31-bt-28-034]). In addition, the ability of MSCs to differentiate into cells of the neuronal lineage has been questioned. In fact, some stressful culture conditions can produce morphological changes and alter protein expression in MSCs without necessarily turning them into neurons. Among these conditions, serum deprivation, cell fusion or the addition of some components to differentiation media (e.g., dimethyl sulfoxide or β-mercaptoethanol) ([@b51-bt-28-034]; [@b45-bt-28-034]; [@b14-bt-28-034]) have been assayed. However, more recent research has demonstrated successful and stable neuronal differentiation corroborated by multiple techniques both *in vitro* and *in vivo* ([@b58-bt-28-034]; [@b95-bt-28-034]; [@b76-bt-28-034]).

MODULATION OF MESENCHYMAL STEM CELLS TO THE NEURONAL LINEAGE
============================================================

Contrary to drug-based treatments, therapies employing living cells have the advantage of dynamically responding to a time-changing environment, rather than being focused on a single way of action ([@b42-bt-28-034]). In order to treat neurological injuries with MSCs, these cells can be obtained from different sources such as the umbilical cord (HU-MSCs) ([@b36-bt-28-034]), bone marrow (BM-MSCs) ([@b54-bt-28-034]), amniotic fluid ([@b88-bt-28-034]) or adipose tissue (AD-MSCs) ([@b27-bt-28-034]). However, no accurate studies comparing the functionality of MSCs according to their source have been conducted. Once implanted in the injured region, MSCs can exert the following therapeutical mechanisms: secretion of neurotrophic factors ([@b63-bt-28-034]), induction of neurogenesis and astroglial activation ([@b90-bt-28-034]), axon growth and enhancement of synaptic connections ([@b56-bt-28-034]), anti-apoptotic, immunomodulatory ([@b83-bt-28-034]; [@b12-bt-28-034]) and antiinflammatory effects ([@b33-bt-28-034]), reduction of oxidative stress ([@b43-bt-28-034]; [@b15-bt-28-034]), secretion of exosomes containing a wide range of bioactive molecules ([@b44-bt-28-034]; [@b79-bt-28-034]), and expression of a great number of genes related to neuronal processes and transcription factors ([@b5-bt-28-034]).

In general, transplanted MSCs are previously reprogrammed *in vitro* with the aim of improving their survival and accelerating their differentiation into nervous cells ([@b50-bt-28-034]; [@b55-bt-28-034]). *In vitro* reprogramming of MSCs towards neuronal lineage can be achieved through four different strategies ([Fig. 1A](#f1-bt-28-034){ref-type="fig"}): psychotropic drugs, small molecules, enriched media and epigenetic modifications. On the contrary, other research groups have transplanted MSCs not previously reprogrammed ([@b9-bt-28-034]), and even followed by the injection of growth factors in the treated zone ([@b49-bt-28-034]).

It is known that some drugs, namely antidepressants and antipsychotics, can increase proliferation and differentiation rates of MSCs into neurons ([@b64-bt-28-034]). These drugs have proved to reverse gray matter loss and slow down the reduction in brain volume in patients with neurodegenerative disorders such as schizophrenia or depression. However, the mechanisms by which this occurs are not completely understood ([@b65-bt-28-034]), although it has been observed that inhibiting glycogen synthase kinase-3β (GSK-3β) plays a key role in the proliferation of hippocampal neuronal precursor cells ([@b60-bt-28-034]). Atypical antipsychotic drugs like risperidone, olanzapine and aripiprazole, and antidepressants like desvenlafaxine ([@b7-bt-28-034]) have proved to increase *in vitro* neurogenesis and neuron maturation in rat models, respectively. Additionally, the antidepressants imipramine, desipramine, fluoxetine and tianeptine have shown improved differentiation efficiency of rat MSCs into neuron-like cells ([@b11-bt-28-034]).

Small molecules are also emerging as cutting-edge tools in the pharmacotherapy of brain injuries. They can imitate the activity of endogenous proteins and modulate certain signaling pathways. Among these small molecules, a plethora of GSK-3β inhibitors stand out, particularly lithium, a mood stabilizer that accumulates in neurogenic brain regions and increases adult hippocampal neurogenesis ([@b10-bt-28-034]; [@b92-bt-28-034]). Vitamin derivatives such as retinoic acid, known to induce differentiation of MSCs into neurogenic cells ([@b28-bt-28-034]; [@b30-bt-28-034]), also play a role in the differentiation of neural progenitors. Finally, [@b4-bt-28-034] tested a combination of SMAD signaling inhibitors (SMAD1/3 and SMAD3/5/8) with chromatin modifying agents (trichostatin A and RG108) and modulators of cAMP levels, showing a high rate of BM-MSCs differentiation into neuron-like cells and an enhanced formation of synaptic-like structures. In addition, enrichment of culture media with growth factors and other inductor substances allow the *in vitro* differentiation of MSCs towards various cell types with morphological and functional differences ([@b97-bt-28-034]; [@b41-bt-28-034]; [@b20-bt-28-034]). Since the publication of the first neuronal differentiation medium for MSCs in 2000 ([@b84-bt-28-034]), a number of media have been used for this purpose. [Table 1](#t1-bt-28-034){ref-type="table"} summarizes the substances most commonly employed and the neuronal markers most frequently studied to evaluate the differentiation efficiency of MSCs.

Epigenetic changes lead MSCs to a particular lineage by repressing genes related to the undifferentiated state and expressing those associated with differentiation ([@b78-bt-28-034]; [@b34-bt-28-034]). A recent study stated that changes in the neuronal phenotype of MSCs can be a result of epigenetic modifications ([@b3-bt-28-034]). Exposing MSCs to epigenetic modifiers and neuronal induction factors turns them into neuronal lineage-like cells, suggesting that cell plasticity can be handled by combining epigenetic modulating enzymes and specific signaling pathways. Nevertheless, the mechanisms by which MSCs undergo trans-differentiation are still unclear. [@b3-bt-28-034] developed a protocol for neuronal differentiation based on testing various epigenetic modulators such as trichostatin (TSA), valproic acid (VPA), sodium butyrate, DNZep, RG108, 5-aza-dC, zebularine or BIX 01294, in combination with substances that promote iPSCs differentiation into neuronal lineage. These authors demonstrated that chromatin-modifying compounds increase the plasticity of already differentiated cells and make them suitable to respond to differentiation-inducing signals. Some studies have shown that the exposure of MSCs to VPA, a histone deacetylase inhibitor, leads to overexpression of specific markers of neural progenitors like GFAP and nestin ([@b18-bt-28-034]). [@b22-bt-28-034] confirmed that TSA and VPA affected the expression of neuronal lineage genes, and inhibited cell proliferation and neurospheres formation in a culture of rat MSCs.

Genetic modifications of MSCs can be an effective method to achieve a faster and more durable neuronal differentiation, either alone or in combination with differentiation media. Genetically modified MSCs have demonstrated the potential to secrete brain-derived neurotrophic factors, such as BDNF, VEGF, NGF, IGF-1 ([@b73-bt-28-034]; [@b29-bt-28-034]; [@b86-bt-28-034]) and neurotrophins ([@b96-bt-28-034]), among others, and to serve as cellular vehicles for pro-drug gene therapy ([@b16-bt-28-034]) to treat neurodegenerative disorders. The manipulation of MSCs towards a desired epigenetic status for their differentiation into the proper neuronal lineages could be the tool for the development of alternative cell therapies focused on neurodegenerative disorders.

CLINICAL TRIALS WITH MESENCHYMAL STEM CELLS FOR THE TREATMENT OF NERVOUS SYSTEM DISORDERS
=========================================================================================

The plasticity of MSCs has allowed the development of numerous clinical trials, many of which have not yet been completed ([Table 2](#t2-bt-28-034){ref-type="table"}). However, data from the most recent ones show that the use of MSCs to treat NS pathologies does not imply adverse effects or structural changes. Furthermore, the increasing amount of positive results *in vivo* in phase I and II trials suggests that the transplantation of MSCs may lead to functional improvements and tissue regeneration.

After trauma, normal brain functioning may be disrupted, producing severe physical and emotional damage, which is known as traumatic brain injury (TBI). It has been shown that MSCs have potential applications in TBI to reduce brain damage and clinical sequelae. In fact, MSCs can reduce inflammation through immunosuppressive mechanisms and induce the secretion of growth factors that benefit neurons ([@b32-bt-28-034]). Two recent clinical trials, NCT02742857 and NCT02525432, use intrathecal and intravenous transplantation of MSCs to improve the prognosis of patients with TBI, although results are ongoing. Stroke occurs when a sudden interruption of blood flow takes place in the brain. Currently, TBI is one of the main objectives for the application of MSCs ([Fig. 1B](#f1-bt-28-034){ref-type="fig"}). The possibility that MSCs may be implanted into injury as self-renewing neuronal cells has been assayed ([@b59-bt-28-034]). In fact, the use of the modified SB623 stem cells in this pathology improved the clinical evolution of the patient for at least one year. Numerous clinical trials are underway using BM-MSCs, HU-MSCs or placenta-derived cells transplanted by different methods to determine the utility of this therapy in stroke ([Table 2](#t2-bt-28-034){ref-type="table"}).

On the other hand, spinal cord injury (SCI) triggers a severe loss of motor, sensory, and autonomic functions that lack proper treatment. The neurological deficit results from the direct trauma associated with a secondary injury characterized by local immune reaction, apoptosis of neurons, tissue atrophy with cavitation and glial scar formation ([Fig. 1C](#f1-bt-28-034){ref-type="fig"}). Recently, it has been demonstrated that MSCs promote the repair of spinal cord tissues in animal models, suggesting their potential clinical use ([@b66-bt-28-034]). A clinical trial using repeated doses of autologous BM-MSCs by subarachnoid route (NCT02165904) showed no secondary effects -at least after one year-, and functional improvements were reported. Some other studies showed similar results (NCT02352077, NCT01909154, NCT01325103).

Multiple sclerosis and amyotrophic lateral sclerosis (ALS) may be excellent candidates for MSCs-based therapies. The former is an inflammatory disease in which activated T cells induce axonal demyelination and neurological disability. The latter is a neurodegenerative disorder characterized by major alterations of the neuromuscular system with an unknown etiology, although the activity of the immune system is thought to play a relevant role. In both conditions, the therapeutic plasticity of MSCs may benefit the evolution and prognosis of the patients ([Fig. 1D](#f1-bt-28-034){ref-type="fig"}) ([@b6-bt-28-034]; [@b47-bt-28-034]). A recent clinical trial employing autologous BM-MSCs intrathecally followed by MSCs conditioned media to treat multiple sclerosis (NCT01895439) showed improvements in all the tests conducted (except for lesion volume), demonstrating the safety and feasibility of this treatment. A more recent study (NCT01933802) using the same cells and route of administration improved muscular strength and bladder function with minor secondary effects. In relation to ALS, a recent phase II study (NCT01777646) showed that MSCs induced the secretion of neurotrophic factors, and slowed its natural progression without adverse effects for at least 6 month. Similar results were observed in other studies employing MSCs from different sources and with different routes of administration (NCT01771640, NCT02290886 and NCT02987413).

Finally, MSCs are being tested in clinical trials in other NS disorders, such as Shy-Drager syndrome, Werdnig-Hoffman disease, Huntington's chorea and Alzheimer's disease ([Table 2](#t2-bt-28-034){ref-type="table"}). Regarding Alzheimer's disease, the use of stem cells can be a hope. However, although some clinical studies support the safety and efficacy of this therapy, there is no unifying hypothesis for an underlying mechanism of action. The presence of neurotrophic factors, the activation of immunomodulatory molecules and the increase in the expression of synaptic proteins have been implicated ([@b8-bt-28-034]). An ongoing phase II clinical trial with autologous AD-MSCs administered intravenously did not show adverse effects after 3 years (NCT03117738). Similar results have been found in other clinical trials (NCT02054208, NCT01547689).

In conclusion, different methods supporting and stimulating endogenous neurogenesis have shown significant beneficial effects on brain regeneration, e.g., improving functions lost by injury or disease. However, it seems that the efficiency of endogenous neurogenesis supported by extrinsic stimuli is not sufficient for the regeneration of large brain deficits.

DIFFICULTIES AND FUTURE PERSPECTIVES ON THE USAGE OF STEM CELLS IN THE CLINIC
=============================================================================

The best pre-clinical results regarding the use of stem cells to treat nervous system diseases have been obtained with an early administration of cells following neuronal injury, aiming to inhibit the initial inflammatory response and to activate the immune cells. There is little evidence supporting significant benefits when cells are administered after one week ([@b85-bt-28-034]). Currently, the clinical usage of autologous MSCs is limited, mainly due to the difficulty of generating large amounts of cells to treat the patient in a short period of time. The high economic cost also constitutes a significant hindrance, especially when it comes to generating, processing and storing stem and progenitor cells before administering them to the patient. Other technical aspects that are worth considering before employing MSCs in the clinic include ([@b13-bt-28-034]): i) difficulty of standardizing isolation protocols; ii) MSCs heterogeneicity, which affects their *in vitro* expansion; iii) long-term expansion of a limited number of clones with loss of multipotency; iv) choice of the route of administration, which can alter the distribution or localization of MSCs in the damaged tissue; v) dose and time of patient's follow-up; or vi) spontaneous transformation of MSCs in other cell types during the proliferative phase, including tumor cells. Although the main objective of these therapies is functional recovery, there are several unspecific effects that stem and progenitor cells can exert, like stabilization of the blood-brain barrier or brain edema in case of trauma. In order to ensure the safety and efficacy of the treatment, monitoring should be conducted by combining magnetic resonance imaging to show the brain injury and perfusion, the study of biological parameters such as systemic concentration of pro- and antiinflammatory cytokines, and neurological tests that allow a comprehensive assessment of the neurological state of the patient.

In neuronal lineage-differentiated cells, not only the genome must be preserved, but also the epigenetic pattern must be carefully considered in order to certify the identity of cells after differentiation so as to guarantee that the cell type used at the beginning of the research is the same as the one transplanted into the patient. Neuronal stem cells can turn into neuronal tumor cells due to epigenetic and genetic modifications, first transforming differentiated cells into more primitive ones, and finally into tumor cells ([@b1-bt-28-034]). However, using autologous cell sources diminishes the risk of malignant transformation. Further studies are required to elucidate the mechanisms underlying stem cell transformation, which will significantly contribute to regulate cell destination and oncogenesis inhibition.

CONCLUSION
==========

It is worth noting that, in spite of promising results from a large number of pre-clinical and clinial trials, MSCs therapies still have significant limitations. It is necessary to isolate and culture homogeneous populations of MSCs, improve the differentiation efficiency and regeneration rate, establish an optimal transplantation methodology and ensure long-term biosecurity after transplantation. It is known that the process of neuronal differentiation is mostly controlled by changes in gene expression, and thus understanding the genetic behavior of MSCs during differentiation would help to create a more effective approach to cell therapy. To date, despite several methods to stimulate neurogenesis -with notable benefits for the patient- are known, their efficiency is not enough to repair the neuronal damage secondary to severe nervous system diseases. In order to restore the normal function of the damaged tissue, conventional therapeutic approaches may not be sufficient. In this regard, combining tissue engineering, pharmacology and classic rehabilitation could be the most promising strategy. Moreover, understanding the regeneration mechanisms of the nervous tissue will allow to coordinate and improve these therapies. New *in vivo* and *in vitro* studies are needed to identify the molecular interactions between the cell graft and the host, eventually leading to a better translation to the clinic from a responsible and accesible perspective.
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![Schematic process of the *in vitro* differentiation of mesenchymal stem cells (MSCs). Differentiation factors as drugs, small molecules, the enrichment of culture media and epigenetics changes (A) make different effects on MSC like increase reactive astrocytosis, synaptogenesis, neurogenesis, myelination, apoptosis inhibition and angiogenesis. In addition, inhibition apoptosis and inflamation are also induced. MSC may be applied to promote remyelination (i.e., multiple sclerosis) where the presence of MSC marks the sites where the oligodendrocyte progenitor cell (OPC) has to join to repair the lost myelin (B). Moreover, MSCs may be used to induce restitution of injured areas and damaged circuitry of the brain after stroke (C). Finally, therapeutic application of MSCs may represent a promising approach in the treatment of spinal cord injury (D).](bt-28-034f1){#f1-bt-28-034}

###### 

*In vitro* neuronal differentiation of MSC. Substances commonly used for neural differentiation and neuronal markers more frequently studied after the differentiation process

  Compounds       Neuronal markers                 Types of MSC    Ref.
  --------------- -------------------------------- --------------- ------------------
  EGF             CHAT, TH, TUB-III, MAP2          AD-MSC          [@b57-bt-28-034]
  Insulin         GFAP, TUB-III                    AD-MSC          [@b89-bt-28-034]
  5-Azacytine     MAP2                             AD-MSC          [@b94-bt-28-034]
  bFGF            GFAP, MAP2, MBP, nestin          UCSC            [@b67-bt-28-034]
  NGF             TUB-III, NF-M, PSD-95            UCSC            [@b39-bt-28-034]
  SHH             Hb-9, Pax-6, NF, CHAT            UCSC            [@b91-bt-28-034]
  cAMP            TUB-III, NSE, MAP2, GFAP         UCSC            [@b70-bt-28-034]
  BDNF            Nestin, NSE, GFAP                BM-MSC          [@b48-bt-28-034]
  DMSO            NSE, GFAP                        BM-MSC          [@b87-bt-28-034]
  Retinoic acid   NF                               BM-MSC          [@b82-bt-28-034]
  BME             Nestin, NSE                      BM-MSC          [@b71-bt-28-034]
  IBMX            TUB-III, GFAP, NF, NeuN, MAP2    BM-MSC / eMSC   [@b93-bt-28-034]
  BHA             MAP2, NSE, GFAP                  BM-MSC          [@b61-bt-28-034]
  LIF             Nestin, TUB-III, GFAP, MBP, TH   hDPSC           [@b17-bt-28-034]

AD-MSC, adipose-derived mesenchymal stem cells; BDNF, brain-derived neurotrophic factor; bFGF, basic fibroblast growth factor; BHA, butylated hydroxyanisole; BM-MSC, bone marrow-derived mesenchymal stem cells; BME, 2-mercaptoethanol; CHAT, choline O-acetyltransferase; DMSO, dimethyl sulfoxide; EGF, epidermal growth factor; eMSC, menstrual blood mesenchymal stem cells; GFAP, glial fibrillary acidic protein; Hb-9, homeobox gene 9; hDPSC, human dental pulp stem cells; IBMX, 3-isobutyl-1-methylxanthine; LIF, leukemia inhibitory factor; MAP2, microtubule-associated protein 2; MBP, myelin basic protein; MSC, mesenchymal stem cells; NCC, neural crest cells; NF, neurofilament; NGF, nerve growth factor; NSE, neuron-specific enolase; Pax-6, paired box protein 6; PSD-95, postsynaptic density protein 95; SHH, sonic hedgehog; TH, tyrosine hydroxylase; TUB-III, ß-tubulin III; UCSC, umbilical cord blood stem cells.

###### 

Clinical trials using MSCs for neural disorders

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Identifier/Country           Study                                                                                                     Phase/Patients   Year   Safety and effectiveness                                Disease
  ---------------------------- --------------------------------------------------------------------------------------------------------- ---------------- ------ ------------------------------------------------------- ---------------------------------
  NCT02742857/India            Intrathecal transplantation of bioactive peptides, MSC and transcranial laser stimulation                 1/20             2017   Ongoing                                                 Traumatic brain injury

  NCT02525432/USA              Intravenous transplantation of autologous BM-MSC                                                          2/55             2017   Ongoing                                                 Traumatic brain injury

  NCT00875654/France           Intravenous injection of autologous BM-MSC                                                                2/31             2017   Ongoing                                                 Stroke

  NCT01287936/USA              Transplantation of modified SB623 stem cells into ischemic, chronic and stable cerebrovascular accident   1--2/18          2016   Cells safe Improvement after 12 months                  Stroke

  NCT01310114/USA              Intravenous administration of placenta-derived cells                                                      2/44             2018   Ongoing                                                 Ischemic stroke

  NCT03356821/Holland          Intranasal transplantation of BM-MSC in perinatal                                                         1--2/10          2017   Ongoing                                                 Arterial infarction

  NCT01678534/Spain            Transplantation of allogeneic AD-MSC                                                                      2/20             2017   Ongoing                                                 Ischemic stroke

  NCT01468064/China            Transplantation of autologous BM-MSC and endothelial progenitors                                          1--2/20          2017   Ongoing                                                 Ischemic stroke

  NCT01922908/USA              Transplantation of autologous BM-MSC                                                                      1--2/48          2017   Ongoing                                                 Ischemic stroke

  NCT03371329/USA              Transplantation of BM-MSC                                                                                 1/12             2017   Ongoing                                                 Intracerebral hemorrhage

  NCT02580019/China            Transplantation of HU-MSC                                                                                 2/2              2017   Ongoing                                                 Ischemic stroke

  NCT02378974 South Korea      Intravenous transplantation of HU-MSC                                                                     1--2/18          2017   Ongoing                                                 Ischemic stroke

  NCT03176498/China            Intravenous transplant of HU-MSC                                                                          1--2/40          2017   Ongoing                                                 Ischemic stroke (convalescence)

  NCT03186456/China            Transplantation of HU-MSC                                                                                 1/40             2017   Ongoing                                                 Ischemic stroke

  NCT01716481/South Korea      Intravenous transplantation of autologous MSC expanded with autologous serum                              3/60             2017   Ongoing                                                 Stroke

  NCT01297413/USA              Transplantation of allogeneic BM-MSC                                                                      1--2/38          2017   Ongoing                                                 Ischemic stroke

  NCT02849613/France           Intravenous transplantation of allogeneic ADSC                                                            2--3/400         2016   Ongoing                                                 Stroke

  NCT02165904/Spain            Subarachnoid transfer of autologous BM-MSC                                                                2/10             2017   No secondary effects (1 year) Functional improvements   Spinal cord injury

  NCT02481440/China            Transplantation of allogeneic umbilical cord-derived MSC                                                  1--2/44          2018   Ongoing                                                 Spinal cord injury

  NCT01676441/South Korea      Autologous MSC transplantation                                                                            2--3/32          2016   Ongoing                                                 Spinal cord injury

  NCT02574585/Brazil           Transfer of autologous BM-MSC                                                                             2/40             2017   Ongoing                                                 Spinal cord (lumbar) injury

  NCT02574572/Brazil           Transfer of autologous BM-MSC                                                                             1/10             2018   Ongoing                                                 Spinal cord (cervical) injury

  NCT02152657/Brazil           Transfer of autologous MSC in spinal cord injuries by percutaneous puncture                               5/1              2017   No publication available                                Spinal cord injury

  NCT02482194/Pakistan         Intrathecal transfer of autologous BM-MSC                                                                 1/9              2016   No secondary effects (2 years)                          Spinal cord injury

  NCT02688049/China            Combined treatment of MSC and NeuroRegen scaffold                                                         1--2/30          2017   Ongoing                                                 Spinal cord injury

  NCT02570932/Spain            Intrathecal transfer of autologous BM-MSC                                                                 2/10             2017   Ongoing                                                 Spinal cord injury

  NCT01769872/South Korea      AD-MSC transplantation                                                                                    1--2/15          2016   No publication available                                Spinal cord injury

  NCT03003364 Spain            Intrathecal transfer of autologous WJ-MSC                                                                 1--2/10          2017   No publication available                                Spinal cord injury

  NCT02352077/China            Transplantation of BM-MSC and NeuroRegen scaffold                                                         1/30             2016   No secondary effects (1 year)\                          Spinal cord injury
                                                                                                                                                                 Small sensorial improvements                            

  NCT02981576 Jordan           Comparison of AD- and BM-MSC transplantation                                                              1--2/14          2017   Ongoing                                                 Spinal cord injury

  NCT02917291/Spain            Transplantation of allogenic AD-MSC combined with H2O2 and HC016 cells                                    1--2/46          2017   Ongoing                                                 Spinal cord injury

  NCT03308565/USA              AD-MSC transplantation in cerebrospinal fluid                                                             1/10             2017   Ongoing                                                 Spinal cord injury

  NCT01909154/Spain            Transfer of autologous BM-MSC                                                                             1/12             2017   No secondary effects\                                   Spinal cord injury
                                                                                                                                                                 Small sensorial improvements                            

  NCT01393977/China            Differences between rehabilitation and transplantation                                                    2/60             2017   No publication available                                Spinal cord injury

  NCT02881489/Poland           Transplantation of autologous BM-MSC                                                                      1/30             2017   Ongoing                                                 Spinal cord injury

  NCT01873547/China            Differences between rehabilitation and transplantation                                                    3/300            2018   No publication available                                Spinal cord injury

  NCT01325103/Brazil           Transplantation of autologous BM-MSC                                                                      1/20             2017   No secondary effects\                                   Spinal cord injury
                                                                                                                                                                 Neurological improvements                               

  NCT01377870/Iran             Evaluation of the autologous MSC transplantation in multiple sclerosis                                    1--2/30          2018   No publication available                                Multiple sclerosis

  NCT01895439/Jordan           Intrathecal administration of autologous BM-MSC                                                           1--2/30          2017   No adverse secondary effects\                           Multiple sclerosis
                                                                                                                                                                 General improvement                                     

  NCT00813969/USA              Autologous MSC transplantation                                                                            1/24             2016   No publication available                                Multiple sclerosis

  NCT01933802/USA              Intrathecal administration of autologous MSC                                                              1/20             2018   Minor secondary effects (24 hours)\                     Multiple sclerosis
                                                                                                                                                                 Improvements in muscular strength and bladder           

  NCT01606215/United Kingdom   Transplantation of MSC                                                                                    1--2/13          2016   No publication available                                Multiple sclerosis

  NCT01745783/Spain            Intravenous transplantation of autologous BM-MSC                                                          1--2/30          2018   No publication available                                Multiple sclerosis

  NCT02611167/USA              Intravenous transplantation of allogeneic BM-MSC                                                          1--2/20          2018   Ongoing                                                 Parkinson

  NCT01609283/USA              Intrathecal transplantation of autologous MSC                                                             1/27             2018   Ongoing                                                 ALS

  NCT01759797/Iran             Intravenous transplantation of autologous MSC                                                             1/6              2016   No secondary effects                                    ALS

  NCT02492516/Iran             Intravenous transplantation of autologous AD-MSC                                                          1/19             2016   No publication available                                ALS

  NCT02987413/Brazil           Intrathecal transplantation of autologous MSC                                                             1/3              2017   No secondary effects (1year)                            ALS

  NCT01771640/Iran             Intrathecal transplantation of autologous MSC                                                             1/8              2018   No secondary effects (6 months)                         ALS

  NCT02917681/Brazil           Intrathecal transplantation of autologous MSC                                                             1--2/28          2016   No secondary effects (10 months)                        ALS

  NCT02290886/Spain            Intravenous transplantation of AD-MSC                                                                     1--2/40          2018   No secondary effects (10 months)                        ALS

  NCT03268603/USA              Transplantation of autologous AD-MSC                                                                      2/60             2018   Ongoing                                                 ALS

  NCT03280056/USA              Intrathecal transplantation of autologous BM-MSC                                                          3/200            2018   Ongoing                                                 ALS

  NCT03296501 Poland           Intraspinal transplantation of AD-MSC                                                                     1/30             2017   Ongoing                                                 ALS

  NCT01777646/Israel           Transplantation of autologous BM-MSC secreting neurotrophic factors                                       2/14             2018   No secondary effects (10 months)                        ALS

  NCT02600130/USA              Intravenous transplantation of MSC versus placebo                                                         1/30             2018   Ongoing                                                 Alzheimer

  NCT02833792/USA              Transplantation of allogeneic MSC                                                                         2/40             2018   Ongoing                                                 Alzheimer

  NCT02054208/South Korea      Transplantation of HU-MSC                                                                                 1--2/45          2017   No secondary effects (2 years)                          Alzheimer

  NCT01547689/China            Transplantation of HU-MSC                                                                                 1--2/30          2016   No secondary effects (10 months)                        Alzheimer

  NCT03117738/USA              Intravenous transplantation of autologous AD-MSC                                                          1--2/60          2018   No secondary effects (3 years)                          Alzheimer

  NCT03172117/South Korea      Transplantation of HU-MSC                                                                                 1--2/45          2017   Ongoing                                                 Alzheimer

  NCT02672306/China            Transplantation of HU-MSC                                                                                 1--2/40          2018   Ongoing                                                 Alzheimer

  NCT02899091/South Korea      Intravenous transplantation of MSC                                                                        1--2/24          2016   Ongoing                                                 Alzheimer

  NCT02315027/USA              Intrathecal transplantation of autologous MSC                                                             1/30             2017   No secondary effects (1 year)                           SDS-MSA

  NCT00911365/South Korea      Transplantation of autologous MSC *versus* placebo                                                        2/27             2017   No secondary effects                                    SDS-MSA

  NCT03265444/South Korea      Transplantation of BM-MSC                                                                                 1/9              2018   Ongoing                                                 MSA

  NCT02855112/Iran             Transplantation of allogeneic AD-MSC                                                                      1--2/10          2017   No secondary effects                                    SMA1

  NCT02728115/Brazil           Intravenous transplantation of autologous MSC                                                             1/6              2017   Ongoing                                                 Huntington's chorea

  NCT03252535/Brazil           Transplantation of MSC                                                                                    2/35             2017   Ongoing                                                 Huntington's chorea
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

AD-MSC, adipose tissue-derived mesenchymal stem cells; ALS, amyotrophic lateral sclerosis; BM-MSC, bone marrow-derived mesenchymal stem cells; HU-MSC, human umbilical mesenchymal stem cells; SDS-MSA, Shy-Drager syndrome (multiple system atrophy); SMA1, spinal muscular atrophy type 1 (Werdnig-Hoffman disease); WJ-MSC, Wharton's jelly-derived mesenchymal stem cells.

[^1]: The first two authors contributed equally to this work.
